Up to now, over 1,000 experimental treatments found in cells and rodents have been difficult to translate to human ischemic stroke. Since ischemia and reperfusion, two separate stages of ischemic stroke, have different pathophysiological mechanisms leading to brain injury, a combination of protective agents targeting ischemia and reperfusion respectively may obtain substantially better results than a single agent. Normobaric hyperoxia (NBO) has been shown to exhibit neuro-and vaso-protective effects by improving tissue oxygenation when it is given during ischemia, however the effect of NBO would diminish when the duration of ischemia and reperfusion was extended. Therefore, during reperfusion drug treatment targeting inflammation, oxidative stress and free radical scavenger would be a useful adjuvant to extend the therapeutic window of tissue plasminogen activator, the only United States Food and Drug Administration (FDA) approved treatment for acute ischemic stroke. In this review, we discussed the neuro-and vaso-protective effects of NBO and recent finding of combining NBO with other drugs.
IntroductIon
Acute ischemic stroke happened when blood vessels were suddenly occluded by a thrombus or embolism followed by the immediate lack of oxygen and glucose to the brain (Lakhan et al., 2013) . A major goal for the treatment of acute ischemic stroke is to promote arterial recanalization to salvage the ischemic penumbra (Ramos-Cabrer et al., 2011) , which is a region of ischemic brain tissue with sufficient energy for short-term survival (Hakim, 1998) . If ischemia persists, the penumbra will progress to permanent damage, primarily driven by ischemia-induced hypoxia and the subsequent energy failure (Dirnagl et al., 1999) . This penumbra concept has inspired the development of two main categories of drugs to treat stroke in the acute phase: drugs interrupting cell death pathways (Reza Noorian et al., 2011) and drugs inducing reperfusion in the ischemic zone REVIEW (Barreto and Alexandrov, 2012) . Neuro-protection alone without restoration of tissue perfusion and vascular integrity may not be adequate for treatment of acute stroke (Zhang et al., 2012) . However, when reperfusion is attained, additional irreversible damage can also develop following reperfusion due to a mechanism of reperfusion injury including inflammation, oxidative stress and excitatory injury (Schaller and Graf, 2004; Pan et al., 2007) . Therefore, combination therapy targeting both ischemia-and reperfusion-induced nerve and blood vessel damage is needed.
EffEct of normobarIc hypEroxIa (nbo) trEatmEnt on IschEmIc strokE
Improving tissue oxygenation has been studied for many years as a simplistic but plausible treatment strategy to reduce ischemic injury. NBO has been suggested as a practical Cocktail treatment, a promising strategy to treat acute cerebral ischemic stroke?
acute-phase treatment to slow down the onset of irreversible injury of the penumbra, thus potentially allowing for delayed or more effective treatment as it is readily available, safe and can be initiated promptly after stroke onset by paramedics (Kim et al., 2005; Henninger and Fisher, 2006; Liu et al., 2009a) . When used as a monotherapy, NBO preserves the ischemic penumbra and reduces ischemic lesion volumes Chiu et al., 2006; Liu et al., 2006; Henninger et al., 2007; Shin et al., 2007;  for review see Qi et al., 2013) . The effect is attributed to the ability of NBO to improve energy metabolism in the ischemic penumbra, as evidenced by elevated interstitial oxygen partial pressure , increased cerebral blood flow and O 2 delivery (Shin et al., 2007) , and reductions in acidosis and ATP deletion (Sun et al., 2011) . More importantly, oxygen therapy does not increase production and damage induced by reactive oxygen species in focal cerebral ischemia (Sun et al., 2014) . However, NBO-afforded early cerebral protection could diminish over time during reperfusion (Kim et al., 2005; Esposito et al., 2013) , the mechanism of ischemia/ reperfusion damage to the blood-brain barrier (BBB) may account for this phenomena (Aronowski et al., 1997) .
EffEct of nbo on prEsErvatIon of thE bbb
IntEgrIty and thE ExtEnsIon of thE thrombolytIc tImE wIndow BBB damage and the strategy to protect vascular integrity Over decade, monotherapy focusing on only neurons has not yielded promising results for human stroke. Expanding the research focus to include other cells and matrix may obtain a more comprehensive and realistic view of treatment of human brain injury (Lo et al., 2004) . The presence of a salvageable penumbra has been widely agreed as the premise for thrombolytic therapy (Foley et al., 2010) , however, BBB integrity is considered to be central to the risks of vasogenic edema and hemorrhage transformation (HT), which are the most feared complication of thrombolytic therapy (Del Zoppo et al., 2009) . BBB damage is a progressive process, with an initial injury resulting from ischemia (Simard et al., 2007; del Zoppo, 2013) , aggravated by reperfusion (Jung et al., 2010) . Due to direct contribution to edema and HT, reperfusion-associated BBB injury has been a topic of intensive investigation, which leads to the identification of several mechanisms accounting for reperfusion BBB injury, such as oxidative stress damage due to increased free radical generation (Liu and Rosenberg, 2005) , inflammatory injury (Schofield et al., 2013) , vascular activation and dysregulated extracellular proteolysis (Rosenberg and Yang, 2007; Jung et al., 2010; Moskowitz et al., 2010) .
Ischemia-induced BBB damage in the early stroke stages is increasingly appreciated to negatively impact the safety and efficacy of thrombolytic therapy for ischemic stroke (Jin et al., 2014) . In the early stage of acute stroke, ischemiainduced hypoxia and the subsequent bioenergetic failure induced irreversible damage to the penumbra, therefore, providing O 2 as soon as possible (through NBO treatment) to alleviate the ischemia induced brain injury and extend the time window of tPA treatment.
Tissue-type plasminogen activator (tPA) thrombolysis and HT tPA dissolves blood clots to restore blood flow to the ischemic brain region and salvage the ischemic brain tissue (Wardlaw et al., 2012; Chapman et al., 2014) . Until now, thrombolysis with tPA within 3 or 4.5 hours after symptom onset is the only FDA approved treatment for acute ischemic stroke (Hacke et al., 2008; Del Zoppo et al., 2009 ). However, brief therapeutic window and the high incidence of HT have profoundly constrained the clinical use of tPA in ischemic stroke patients.
Effect of NBO on extension of tPA thrombolytic window
Since NBO treatment during cerebral ischemia significantly alleviates BBB disruption and reduces edema formation (Liu et al., 2008; Liu et al., 2009b) and delaying thrombolytic therapy dramatically increases the risk of hemorrhage (Hatcher and Starr, 2011) , it is rational to combine NBO with tPA to reduce thrombolysis reperfusion-associated complications (Liu et al., 2009a; Sun et al., 2011) .
The potential of the combination NBO treatment with tPA thrombolysis was recognized several years ago (Henninger and Fisher, 2006; Fujiwara et al., 2009) . A previous study has demonstrated that a combination treatment with NBO and delayed tPA treatment at 4.5 hours after stroke onset significantly reduces tPA-associated mortality, alleviates cerebral edema following hemorrhage, and decreases MMP-9 augmentation in a rat model of stroke (Liu et al., 2009a) . It has been reported that a combination therapy of NBO and tPA does not increase hemorrhage volume at 10 hours or occurrence of confluent petechial hemorrhages at 24 hours in a rat model of thromboembolic stroke (Henninger et al., 2009) . NBO can increase the safety of delayed tPA thrombolysis in stroke (Liu et al., 2009a) , extend the time window for tPA, but not increase superoxide generation or MMP-9 in the brain (Kim et al., 2005) . Therefore, co-administration of NBO to tPA is safe. NBO treatment shortly after ischemia onset and tPA therapy at a dealyed time point may represent a safe and effective strategy for acute stroke treatment (Henninger et al., 2009) .
Recently, Liang et al. (2015) showed that early NBO treatment alleviated ischemic BBB damage and significantly improved the outcome of delayed tPA treatment, providing new evidence supporting NBO as an effective adjunctive therapy to expand the therapeutic time window of acute ischemic stroke for tPA.
Nonaka and colleagues showed that combination therapy of NBO plus edaravone showed more beneficial effects than monotherapy by preventing the neuronal damage after focal cerebral ischemia and reperfusion in mice. Their results showed significantly better neurological functions, less infarct volume as well as less TUNEL-positive cells in the ischemic boundary zone both in cortex and subcortex at 22 hours after reperfusion than the two monotherapy groups (Nonaka et al., 2008) . These results suggest that combination therapy with NBO plus edaravone prevented the neuronal damage after focal cerebral ischemia and reperfusion in mice.
NBO plus melatonin
Melatonin is a potent free radical scavenger with excellent BBB permeability (Galano et al., 2014) , which has been shown to protect brain against focal cerebral ischemia in both mice (Zou et al., 2006; Tai et al., 2010; Yang et al., 2014) and rats (Pei et al., 2003; Villapol et al., 2010; Jang et al., 2012) . Therefore, melatonin may augment the survival-promoting action of NBO. Beker and colleagues have examined the effect of NBO treatment alone or in combination with melatonin after focal cerebral ischemia. They reported that combined NBO and melatonin synergistically reduces neuronal injury after mild focal cerebral ischemia induced by 30-minute MCAO. Combination therapy of NBO and melatonin regulated levels of phosphorylated Akt, antiapoptotic Bcl-xL, pro-apoptotic Bax and endothelial NO synthase, as well as reduced neuronal injury, neurological deficits, infarct volume and BBB permeability which has been found by NBO and particularly melatonin treatment alone (Beker et al., 2015) .
NBO plus cilostazol
Cilostazol, a selective inhibitor of phosphodiesterase-3, has been reported to exert neuroprotection against acute brain injury after cerebral ischemia in rodents (Choi et al., 2002; Lee et al., 2003) . Nonaka and colleagues demonstrated that after focal cerebral ischemia, acute and subacute lesion volumes were significantly reduced in the combination group but not in the two monotherapy groups. Compared to the monotherapy, the combination therapy increased endothelial nitric-oxide synthase (eNOS) activity in the lesion area after ischemia. Combination therapy with NBO plus cilostazol protected against focal cerebral ischemia/reperfusion injury in mice by improvement of regional cerebral blood flow (rCBF) after reperfusion, in part in association with eNOS activity (Nonaka et al., 2009 ).
NBO plus ethonal (EtOH)
EtOH consumption is inversely associated with the risk of ischemic stroke, suggesting a neuro-protection as a potential neuroprotectant for acute ischemic stroke (Wang combInatIon trEatmEnt wIth nbo Until now, researchers have failed to translate over 1,000 experimental treatment methods in cells and rodents to therapy of humans (O'Collins et al., 2006) . Since the monotherapy did not work as expected, combinational therapeutic approaches targeting different stages of acute stroke may be an ideal strategy (Rogalewski et al., 2006; Zhang et al., 2012) .
NBO has been shown to effectively reduce tissue infarction and protect the BBB in animal ischemic stroke models (Singhal et al., 2002; Jin et al., 2013; Liang et al., 2015) . The neuro-and vaso-protection make NBO a promising approach to expand the narrow time window of the reperfusion therapies for ischemic stroke (Henninger and Fisher, 2006; Liang et al., 2015) . But its effect was diminished with extension of ischemia and reperfusion. Therefore, either combating inflammation, clearing the free radical, antagonizing glutamate, inhibiting the platelet accumulation, or reducing excessiveγ-aminobutyrie acid (GABA)-mediated tonic inhibition (ethonal treatment) will reduce the reperfusion-induced damage (Clarkson et al., 2010) .
NBO plus minocycline
Inflammatory reactions occurring in the brain after ischemia may contribute to secondary damage to BBB and brain tissue (Wang et al., 2007) . Minocycline, a tetracycline antibiotic, has been shown to protect against reperfusion-induced injury through its anti-inflammatory (Yrjanheikki et al., 1999 ), anti-apoptotic (Arvin et al., 2002 Friedlander, 2003) , and BBB-protecting actions Xu et al., 2004) . Animal studies and early phase clinical trials showed that minocycline, even when administered at delayed time points, is neuroprotective (Xu et al., 2004; Hewlett and Corbett, 2006; Hayakawa et al., 2008; Fagan et al., 2010) .
Jin and colleagues demonstrated that the combination of NBO and minocycline results in greater neuroprotective effects than each individual treatment in a rat model of transient focal cerebral ischemia, NBO plus minocycline effectively provides greater neuro-and vaso-protective effects than monotherapy by inhibiting matrix metalloproteinsase (MMP)-2/9-mediated occludin degradation and attenuation of caspase-dependent and independent apoptotic pathways (Jin et al., 2013) .
NBO plus edaravone
Besides inflammation, reperfusion produces a lot of free radical and free radical could damage the brain (Liu and Rosenberg, 2005 ). An alternative strategy to reduce reperfusion induced injury is to clear the free radical. Edaravone, a potent scavenger of hydroxyl radicals, has been demonstrated to have beneficial effects when combined with NBO. reperfusion induced injury, thereby producing improved outcomes when combination therapy is used.
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The authors declare no competing financial interests. (Geng et al., 2013a, b) . Acute EtOH treatment has been shown to reduce BBB dysfunction following ischemia/reperfusion injury (Zeng et al., 2012) . Combination therapy with NBO and EtOH showed greater neuroprotection than monotherapy alone. Compared to stroke without treatment, monotherapy with NBO and/or EtOH demonstrated reductions in infarct volume and neurological deficits. The greatest neuro-protection was found in combination therapy group associated with the largest reductions in ADP/ATP ratios, reactive oxygen species levels, and nicotinamide adenine dinucleotide phosphate oxidase activity (Geng et al., 2013a, b) .
Because both EtOH and NBO are readily available, inexpensive and easy to administer, their combination is attractive and could be implemented in the clinics shortly after stroke (Geng et al., 2013a, b) .
NBO plus semifluorinated alkane (SFA)-containing emulsion (artificial oxygen carrier)
NBO preserves the ischemic penumbra and reduces ischemic lesion volume by improving tissue oxygenation Chiu et al., 2006; Liu et al., 2006; Henninger et al., 2007; Shin et al., 2007) . The neuroprotective effects of NBO will be amplified if blood oxygen transport capacity could be enhanced. Seiffge and colleagues investigated the neuroprotective effects of increasing the blood oxygen transport capacity by applying an SFA-containing emulsion when transient focal ischemia rats received NBO treatment. Their results showed that oxygen delivery by an artificial oxygen carrier in conjunction with NBO is superior to NBO alone and combination treatment significantly reduced the infarction volume by alleviating the severity of hypoxia to a level sufficient to prevent cells from transition into irreversible damage. Administration of an SFA emulsion in conjunction with NBO is easily afforded in the pre-hospital phase. It may not only provide a significant neuroprotective effects but also expand the time window for ischemic stroke therapy (Seiffge et al., 2012) .
conclusIon
Combination therapy with NBO plus drugs offers enhanced neuroprotective effects through cooperative intervention of both ischemia and reperfusion stages. As a result, NBO has the potential to not only expand the therapeutic time window for tPA administration, but also reduce subsequent
